This website is intended for healthcare professionals only.
TREATING mPaCa IN 2025:
NEW GUIDELINES, NEW DATA, NEW INSIGHTS​
Profesor Gerald Prager MD, PhD Director of the GI Cancer Program of the Department of Medical Oncology, Medical University of Vienna and Comprehensive Cancer Center, Vienna
Profesor Holger Rumpold is the Head of the Department of Hematology and Medical Oncology at Ordensklinikum Linz, the leading oncology reference hospital in Upper Austria. For many years, Holger Rumpold has been instrumental in establishing a dedicated cancer center including gastrointestinal cancers and is engaged in research focusing on real-world evidence in several tumor entities.
This webinar explores the latest advances in the treatment of metastatic pancreatic cancer (mPaCa), with a focus on the new recommendations in the 2025 ESMO guidelines and updated data on the NALIRIFOX regimen. Drawing on data from the NAPOLI-3 trial and the latest Austrian real-world evidence (RWE) studies, as well as a real-life case study of a long-term survivor, the speakers will discuss the efficacy and tolerability of the NALIRIFOX regimen, and which patient profiles are likely to benefit from a better long-term response.
Key points covered
A webinar on the latest advances in metastatic pancreatic cancer highlights 2025 ESMO guideline updates, NALIRIFOX data from trials and real-world evidence, and patient profiles most likely to benefit.
The new ESMO 2025 guidelines recommend NALIRIFOX as the first-line treatment for patients with metastatic pancreatic adenocarcinoma (mPaCa) who are in good general health (ECOG PS 0–1), followed by gemcitabine-based treatment as the second-line therapy.
Austrian real-world data confirm the results of the NAPOLI-3 trial on NALIRIFOX, particularly in patients who meet the inclusion criteria. These patients experience prolonged median survival and a significant treatment-free interval (mTFS).
A US comparative analysis showed that median overall survival was significantly longer with NALIRIFOX in NAPOLI-3 than in cohorts aligned with NAPOLI-3 who were treated with FOLFIRINOX or mFOLFIRINOX, reinforcing the value of the NALIRIFOX regimen in clinical practice.
A post hoc analysis identified the characteristics of patients who achieved a survival of at least 18 months with NALIRIFOX, highlighting the importance of dose reductions, as well as the initial clinical profile.
Webinar highlights
Webinar Replay
Featured Speakers
Profesor Prager
Profesor Prager MD, PhD is the Director of the GI Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center, Vienna. He leads the Unit for Precision Medicine in Cancer and is an Associate Professor of Medicine, Board Certified for Internal Medicine, Hematology, and Medical Oncology. Prof Prager graduated from the Medical School of the University of Vienna and completed his postdoctoral training at the University of California, San Diego, USA and was a Visiting Professor at the Norris Cancer Center, University of Southern California, Los Angeles, USA in 2011. Prof Prager’s main research interests focus on translational research and (tumor-) angiogenesis and his work was honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
Profesor Rumpold
Profesor Holger Rumpold is the Head of the Department of Hematology and Medical Oncology at Ordensklinikum Linz, the leading oncology reference hospital in Upper Austria. For many years, Holger Rumpold has been instrumental in establishing a dedicated cancer center including gastrointestinal cancers and is engaged in research focusing on real-world evidence in several tumor entities.Â
